Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545901 | 0.90 | L3MBTL1 (0.38) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5545793 | 0.90 | L3MBTL1 (0.38) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5546812 | 0.88 | CNR2 (0.41) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5545883 | 0.88 | NAMPT (0.37) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5545372 | 0.86 | CNR2 (0.45) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5545541 | 0.85 | PIK3CA (0.48) | CNR2CNR1NAMPTHPGD | |
| SCHEMBL5547227 | 0.83 | GRIN1 (0.46) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5545514 | 0.83 | GRIN1 (0.44) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5545823 | 0.83 | CNR2 (0.39) | CNR2L3MBTL1CNR1MEN1KMT2A | |
| SCHEMBL5546492 | 0.83 | CNR2 (0.39) | CNR2L3MBTL1CNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | CNR2 4810/4885L3MBTL1 1408/4885CNR1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.